TD Asset Management
GBT

TD Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

TD Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-64,808
Closed -$2.07M – 1526
2022
Q2 		$2.07M Sell
64,808
-7,666
-11% -$224K ﹤0.01% 997
2022
Q1 		$2.51M Sell
72,474
-32,112
-31% -$960K ﹤0.01% 1016
2021
Q4 		$3.06M Buy
104,586
+34,512
+49% +$1.07M ﹤0.01% 1020
2021
Q3 		$1.78M Hold
70,074
– – ﹤0.01% 1122
2021
Q2 		$1.92M Sell
70,074
-14,782
-17% -$577K ﹤0.01% 1111
2021
Q1 		$3.46M Buy
84,856
+3,070
+4% +$141K ﹤0.01% 933
2020
Q4 		$3.54M Sell
81,786
-2,225
-3% -$110K ﹤0.01% 883
2020
Q3 		$4.63M Sell
84,011
-9,717
-10% -$618K 0.01% 725
2020
Q2 		$5.92M Sell
93,728
-4,854
-5% -$333K 0.01% 618
2020
Q1 		$5.04M Sell
98,582
-10,047
-9% -$673K 0.01% 620
2019
Q4 		$8.63M Buy
108,629
+24,900
+30% +$1.48M 0.01% 587
2019
Q3 		$4.06M Buy
83,729
+7,738
+10% +$403K 0.01% 732
2019
Q2 		$4M Buy
75,991
+10,496
+16% +$603K 0.01% 736
2019
Q1 		$3.47M Buy
65,495
+3,400
+5% +$167K 0.01% 782
2018
Q4 		$2.55M Buy
62,095
+634
+1% +$23.8K ﹤0.01% 846
2018
Q3 		$2.34M Buy
61,461
+10,800
+21% +$478K ﹤0.01% 953
2018
Q2 		$2.29M Buy
50,661
+2,600
+5% +$118K ﹤0.01% 922
2018
Q1 		$2.32M Buy
48,061
+13,986
+41% +$780K ﹤0.01% 857
2017
Q4 		$1.34M Buy
+34,075
New +$1.27M ﹤0.01% 974

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TD Asset Management's GBT Position: Q3 2022 in Review

TD Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 64,808 shares — an estimated $2.07M sold.

TD Asset Management first reported a position in GBT in Q4 2017 and held it in 19 quarters. The position peaked at $8.63M in Q4 2019. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • TD Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • TD Asset Management sold 64,808 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $2.07M.
  • TD Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 19 quarters.
  • TD Asset Management's Global Blood Therapeutics, Inc. position peaked at $8.63M in Q4 2019.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on TD Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.